Pharmaceuticals — Selling and other commercial expenses
Vertex Pharmaceuticals Pharmaceuticals — Selling and other commercial expenses increased by 14.6% to $318.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 36.5%, from $233.60M to $318.80M. Over 3 years (FY 2022 to FY 2025), Pharmaceuticals — Selling and other commercial expenses shows an upward trend with a 33.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase relative to revenue may signal higher competition or the launch of new products requiring significant promotion.
Detailed definition
Operating costs related to marketing, sales force support, and commercial distribution of pharmaceutical products. This...
Peer comparison
Standardized as 'Selling, General, and Administrative' (SG&A) or 'Selling' expenses.
vrtx_segment_pharmaceuticals_selling_and_other_commercial_expensesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $117.23M | $117.23M | $117.23M | $117.23M | $148.10M | $148.10M | $148.10M | $148.10M | $191.70M | $196.30M | $216.90M | $233.60M | $241.10M | $264.60M | $278.30M | $318.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +26.3% | +0.0% | +0.0% | +0.0% | +29.4% | +2.4% | +10.5% | +7.7% | +3.2% | +9.7% | +5.2% | +14.6% |
| YoY Change | — | — | — | — | +26.3% | +26.3% | +26.3% | +26.3% | +29.4% | +32.5% | +46.5% | +57.7% | +25.8% | +34.8% | +28.3% | +36.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pharmaceuticals — selling and other commercial expenses?
- Vertex Pharmaceuticals (VRTX) reported pharmaceuticals — selling and other commercial expenses of $318.80M in Q4 2025.
- How has Vertex Pharmaceuticals's pharmaceuticals — selling and other commercial expenses changed year-over-year?
- Vertex Pharmaceuticals's pharmaceuticals — selling and other commercial expenses increased by 36.5% year-over-year, from $233.60M to $318.80M.
- What is the long-term trend for Vertex Pharmaceuticals's pharmaceuticals — selling and other commercial expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's pharmaceuticals — selling and other commercial expenses has grown at a 33.0% compound annual growth rate (CAGR), from $468.90M to $1.10B.
- What does pharmaceuticals — selling and other commercial expenses mean?
- Costs incurred to market and sell the company's drugs to healthcare providers and patients.